Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study aims to predict diabetes risk from common transplant drug

NCT ID NCT03640026

Knowledge-focused Sponsor: Centre Hospitalier Departemental Vendee Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the drug tacrolimus, often used after kidney transplants, affects blood sugar and insulin in people with kidney failure who are waiting for a transplant. Researchers wanted to find early signs of diabetes risk so doctors could adjust treatment. The study was terminated early and involved 61 adults on hemodialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tacrolimus
What this could lead to
If successful, this could help doctors identify patients at risk for tacrolimus-induced diabetes before kidney transplant, allowing them to choose safer immunosuppressants.
What could go wrong
This was a small, terminated Phase 4 study with only 61 participants. Results may not be conclusive or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

61 people

The number who actually took part.

Started

Mar 2019

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patient eligible for kidney transplantation at the Nantes University Hospital * Hemodialysis patient in one of the participating centres * Patient who is able to understand the proposed protocol and has given free and informed consent * Patient with affiliation to the French social security system. Exclusion Criteria: * Personal history of diabetes treated or untreated * Temporary contraindication for carcinological reasons * Immunosuppressive treatment in the 6 months prior to inclusion * Macrolide Allergies * Hypersensitivity to the excipients used in the composition of tacrolimus * Intolerance to the HGPO test * Progressive infectious outbreak * Hepatic insufficiency * Intercurrent infectious pathology * Patient under guardianship, curatorship, legal protection measure, or deprived of liberty * Pregnant women, breastfeeding, or non-menopausal woman who refuses contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney failure, chronic

Contacts and locations

Locations

  • Centre Hospitalier Départemental Vendée

    La Roche-sur-Yon, France

  • Centre Hospitalier Universitaire Nantes

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.